Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Travere Therapeutics Inc (NQ: TVTX )

17.75 -0.35 (-1.93%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Travere Therapeutics Inc

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Back To Back Trial Failures: Analyst Weighs In On Travere Therapeutics' Prospects, Challenges
William Blair downgraded Travere Therapeutics Inc (NASDAQ: TVTX)  
Via Benzinga
Dow Tumbles 200 Points; Darden Restaurants Posts Upbeat Profit
U.S. stocks traded lower toward the end of trading, with the Dow Jones falling around 200 points on Thursday. The Dow traded down 0.58% to 34,239.48 while the NASDAQ fell 1.20% to 13,307.77. The S&P... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Seelos Therapeutics Shares Are Trading Lower By 31%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares climbed 81.5% to $0.2793 after jumping 64% on Wednesday. 
Via Benzinga
Analyst Ratings for Travere Therapeutics
Via Benzinga
Why Shares of Travere Therapeutics Are Slumping Thursday
A mixed trial could hurt a kidney drug's chances of full approval. 
Via The Motley Fool
Why Former Highflier Travere Therapeutics Just Crashed 41% To A Decade-Low
It's now up to the FDA whether the company's key drug remains on the market. 
Via Investor's Business Daily
Exposures Product Safety
Stocks That Hit 52-Week Lows On Thursday
  During the session on Thursday, 461 stocks hit new 52-week lows. 
Via Benzinga
The Latest Analyst Ratings for Travere Therapeutics
Via Benzinga
Gold Down Over 1%; FedEx Shares Rise On Earnings Beat
U.S. stocks traded lower midway through trading, with the Dow Jones falling around 150 points on Thursday. The Dow traded down 0.46% to 34,284.15 while the NASDAQ fell 1.05% to 13,327.80. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures US Equities
Nasdaq Down Over 1%; US Initial Jobless Claims Fall More Than Expected
U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 150 points on Thursday. Following the market opening Thursday, the Dow traded down 0.56% to 34,248.45 while the NASDAQ fell... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Kidney-Disease Focused Travere Therapeutics Stock Trading Lower Today?
Travere Therapeutics Inc (NASDAQ: TVTX) announced 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Earnings Scheduled For August 3, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million. 
Via Benzinga
Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan
From Travere Therapeutics, Inc.
Via GlobeNewswire
Broadcom, KB Home And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures traded lower this morning on Thursday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Evercore ISI Group Maintains Outperform Rating for Travere Therapeutics: Here's What You Need To Know
Via Benzinga
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
EXCLUSIVE: Kidney Care Revolution? How Swedish Biopharma Calliditas Aims To Tackle A Rare Disease With 'Unique, But Pretty Simple' Drug
Calliditas, a rare disease company focused on kidney ailments, is optimistic of its lead drug taking off in a big way. 
Via Benzinga
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics
From Mirum Pharmaceuticals, Inc.
Via Business Wire
Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
NASDAQ: TVTX Investor Notice: Investigation Concerning Potential Securities Laws Violations by Travere Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 08/10/2023 -- Travere Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Travere Therapeutics Reports Second Quarter 2023 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
3 Small-Cap Stocks That Could Be Big-Time Winners
These stocks come with significant risks. But they could generate huge returns over time. 
Via The Motley Fool
Biotech Stock Travere Therapeutics Is Trading At A Deep Discount: JPMorgan
Travere Therapeutics shares have lost nearly 30% since early May. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023
Via Benzinga
Travere Therapeutics to Report Second Quarter 2023 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.